Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
CBC Radio, 07 April 2017
Scandal on Wall Street didn’t end with 2008’s financial crisis. New Yorker staff writer Sheelah Kolhatkar chronicles the rise and fall of the prominent hedge fund SAC Capital in a new book, Black Edge: Inside Information, Dirty Money, and the Quest to Bring Down the Most Wanted Man on Wall Street.
Kolhatkar explains how insider trading allegations dogged the company and its ultra-rich founder, Steven Cohen. Cohen “was an iconic figure in the financial industry,” she tells The Current’s Friday host Piya Chattopadhyay. Continue reading “Article: How Wall Street billionaire Steve Cohen survived an insider trading scandal”